TITLE

FDA Approves Glaxo Welcome's Lotronex for Irritable Bowel

PUB. DATE
March 2000
SOURCE
Worldwide Biotech;Mar2000, Vol. 12 Issue 3, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that the United States Food and Drug Administration has approved the medicine Latronex for use in treating females with irritable bowel syndrome.
ACCESSION #
2889684

 

Related Articles

  • FDA approves restricted marketing of alosetron. LoBuono, Charlotte // Drug Topics;Jul2002, Vol. 146 Issue 13, p18 

    Reports on the approval of the U.S. Food and Drug Administration of restricted marketing of alosetron for the treatment of irritable bowel syndrome. Reasons for withdrawing the drug in 2000; Components of the alosetron risk management program; Recommended starting dose for the drug.

  • Tegaserod. Zimmermann, Anthony E. // Formulary;Sep2002, Vol. 37 Issue 9, p449 

    Reports the approval of Tegaserod by Food and Drug Administration for the short-term treatment of irritable bowel syndrome (IBS) in women in the U.S. Lack of tegaserod of electrocardiographic effects; Adverse effect of the drug; Benefits of Tegaserod for women with constipation-predominant IBS....

  • Novartis' Zelnorm 'not approvable'  // Medical Marketing & Media;Aug2001, Vol. 36 Issue 8, p29 

    Reports on the issuance of a 'not approval' letter by the U.S. Food and Drug Administration to Novartis for Zelnorm, a drug developed by Novartis for irritable bowel treatment. Request for additional data on gall bladder surgery; Petition from the Public Citizen organization; Response of Novartis.

  • NEWSLINE: Two IBS-D Treatments Gain Approval.  // Monthly Prescribing Reference;Jul2015, Vol. 31 Issue 7, pA8 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Viberzi from pharmaceutical company Actavis PLC and Xifaxan 550mg from Salix which are both for treatment of irritable bowel syndrome with diarrhea.

  • FDA approves two IBS drugs. Mullard, Asher // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p449 

    The article reports on the U.S. Food and Drug Administration's approval of two drugs for irritable bowel syndrome (IBS) with diarrhoea, the eluxadoline developed by Allergan and the rifaximin from Valeant, in May 2015.

  • Help For Women Who Have Constipation-Predominant IBS.  // RN;Oct2002, Vol. 65 Issue 10, p98 

    Reports that the U.S. Food and Drug Administration has approved tegaserod maleate (Zelnorm) for the short-term treatment of constipation-predominant irritable bowel syndrome. Mechanism of action of the drug.

  • FDA Approval for Alosetron Re--introduction. Torrey, Brian // American Family Physician;8/1/2002, Vol. 66 Issue 3, p517 

    Reports on the approval of the U.S. Food and Drug Administration for the reintroduction of alosetron hydrochloride under restricted conditions of use. Use of the drug for women with irritable bowel syndrome.

  • New Therapies for Irritable Bowel Syndrome. Voelker, Rebecca // JAMA: Journal of the American Medical Association;7/7/2015, Vol. 314 Issue 1, p17 

    The article announces the approval by the U.S. Food and Drug Administration (FDA) of the drugs eluxadoline marketed as Viberzi and rifaximin marketed as Xifaxan, for the treatment of bowel syndrome with diarrhea (IBS-D) in adults.

  • My beautiful COLONOSCOPY. Gardner, Sharon // New Mobility;Jan2010, Vol. 21 Issue 196, p35 

    The article provides information on the Angel of Water, a unique piece of equipment for an open-system colonic, invented by colon hydrotherapist Rocco Bruno in the U.S. It states that Angel of Water is a Food and Drug Administration (FDA)-registered class II device for medical colon cleansing....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics